Skip to main content

Valneva SE (VALN)

NASDAQ: VALN · IEX Real-Time Price · USD
45.00 0.16 (0.36%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap2.20B
Revenue (ttm)134.54M
Net Income (ttm)-78.53M
Shares Out48.94M
EPS (ttm)-1.60
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume70,359
Open44.30
Previous Close44.84
Day's Range43.68 - 45.39
52-Week Range24.16 - 59.15
Beta0.91
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 18, 2021

About VALN

Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. We take a highly specialized and targeted approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options. We then apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities...

IndustryBiotechnology
IPO DateMay 6, 2021
CEOThomas Lingelbach
Employees700
Stock ExchangeNASDAQ
Ticker SymbolVALN
Full Company Profile

Financial Performance

In 2020, Valneva's revenue was 110.32 million, a decrease of -12.58% compared to the previous year's 126.20 million. Losses were -64.39 million, 3,592.3% more than in 2019.

Financial numbers in millions EURFinancial Statements

News

Valneva (VALN) Reports Positive Data From COVID Vaccine Study

Valneva's (VALN) shares surge after its COVID vaccine demonstrates superiority over AstraZeneca's COVID vaccine in a phase III study.

4 days ago - Zacks Investment Research

These 2 Nasdaq Biotechs Are Making Huge Premarket Moves Monday

The Nasdaq looks poised to open slightly lower after a strong week.

Other symbols:AZNRVNC
5 days ago - The Motley Fool

Why Are Valneva's Shares Trading Higher Monday Premarket?

Valneva SE's (NASDAQ: VALN) COVID-19 vaccine elicits a robust immune response with far fewer side effects than the Oxford/AstraZeneca plc's (NASDAQ: AZN) jab, according to Phase 3 trial results. Valneva...

5 days ago - Benzinga

Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001

Saint Herblain ( France), October 18 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive topline results from the Phase 3 pivotal trial Cov-Com...

5 days ago - GlobeNewsWire

Valneva Announces the Cancellation of Ordinary Shares Held by the Company following Termination of its Liquidity Agre...

Saint- Herb lain (France) , October 4 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Management Board has decided, during a meeting today,...

2 weeks ago - GlobeNewsWire

Valneva to Present and Hold Investor Meetings at the Guggenheim Vaccines and Infectious Disease Conference

Saint- Herb lain (France) , September 30 , 2 021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in...

3 weeks ago - GlobeNewsWire

Valneva, Pfizer Lyme Disease Vaccine Candidate Drops-Off After 18 Months

Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) have announced more positive Phase 2 results, including the booster response, for their Lyme disease vaccine candidate VLA15. The 246-subject study i...

Other symbols:PFE
3 weeks ago - Benzinga

Valneva, Pfizer's Phase 2 Data Suggests Booster Strategy For Lyme Disease Vaccine Candidate

Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) have announced more positive Phase 2 results, including the booster response, for their Lyme disease vaccine candidate VLA15. The 246-subject study i...

Other symbols:PFE
3 weeks ago - Benzinga

Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Cand...

Saint- Herblain ( France) and New York (United States) , September 28 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE), today announced f...

Other symbols:PFE
3 weeks ago - GlobeNewsWire

Valneva Continues To Expand COVID-19 Vaccine Candidate Trials

Valneva SE (NASDAQ: VALN) has commenced recruitment of adolescents in its pivotal Phase 3 trial for its inactivated COVID-19 vaccine candidate VLA2001 in the U.K. Topline results from the trial, dubbed ...

1 month ago - Benzinga

Valneva Continues Expansion of Clinical Trials of its Inactivated COVID-19 Vaccine Candidate VLA2001

Saint- Herb lain (France ) , September 23 , 2021 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that it has commenced recruitment of adolescents in its pi...

1 month ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

New York, New York--(Newsfile Corp. - September 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are adv...

1 month ago - Newsfile Corp

UK cancels Covid vaccine deal with French firm Valneva

Government serves notice to terminate contract over allegations of a ‘breach of obligations'

1 month ago - The Guardian

Valneva: U.S. DoD Exercises First Year Option on IXIARO® Supply Contract

Saint Herblain ( France), September 3 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today announced that the U.S. Department of Defense (DoD) has exercised the fir...

1 month ago - GlobeNewsWire

Valneva to Participate in Goldman Sachs Eleventh Annual Biotech Symposium

Saint- Herb lain (France) , September 1 , 2 021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will participate in 1-on-1 meeti...

1 month ago - GlobeNewsWire

Valneva (VALN) Begins Submission for COVID-19 Vaccine in UK

Valneva (VALN) starts rolling submission for the initial approval of its COVID-19 vaccine candidate, VLA2001, in the United Kingdom.

2 months ago - Zacks Investment Research

Valneva Commences Rolling Submission to MHRA for its Inactivated, Adjuvanted COVID-19 Vaccine

Saint-Herblain (France), August 23, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on prophylactic vaccines for infectious diseases, today commenced rolling s...

2 months ago - GlobeNewsWire

Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate

Saint-Herblain (France), August 11th, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for inf...

2 months ago - GlobeNewsWire

Valneva Reports H1 2021 Financial Results and Provides Business Update

Key R&D Milestones Achieved

2 months ago - GlobeNewsWire

Valneva Announces Positive Phase 3 Pivotal Results for its Single-Shot Chikungunya Vaccine Candidate

Saint Herblain ( France), August 5 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infe...

2 months ago - GlobeNewsWire

Valneva Appoints Peter Buhler as Chief Financial Officer

Saint- Herblain (France), July 29 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infec...

2 months ago - GlobeNewsWire

Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate

Saint- Herblain ( France) and New York, NY , July 19 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic...

Other symbols:PFE
3 months ago - GlobeNewsWire

7 Stocks to Buy if the Third Covid Wave Intensifies

Stocks to buy as the third Covid-19 wave intensifies with the delta variant being dominant globally. Stocks for healthy near-term returns.

Other symbols:ATVIDASHNEMNFLXNLSZM
3 months ago - InvestorPlace

Valneva's Chikungunya Vaccine Candidate Gets FDA Breakthrough Tag

The FDA grants Breakthrough Therapy Designation to Valneva SE's (NASDAQ: VALN) single-shot chikungunya vaccine candidate, VLA1553. This new U.S. milestone comes in addition to the FDA Fast Track designa...

3 months ago - Benzinga

Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Rela...

Saint- Herblain (France), July 6 , 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infect...

3 months ago - GlobeNewsWire